Difference between revisions of "Dactinomycin (Cosmegen)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Uterine" to "[[Category:Endometrial") |
Warner-admin (talk | contribs) m (Text replacement - "Uterine cancer" to "Endometrial cancer") |
||
| Line 11: | Line 11: | ||
*[[Osteosarcoma]] | *[[Osteosarcoma]] | ||
*[[Soft tissue sarcoma|Rhabdomyosarcoma]] | *[[Soft tissue sarcoma|Rhabdomyosarcoma]] | ||
| − | *[[ | + | *[[Endometrial cancer]] |
==Patient drug information== | ==Patient drug information== | ||
Revision as of 03:44, 20 November 2018
General information
Class/mechanism: Antibiotic oncologic, intercalates between guanine and cytosine DNA base pairs, inhibiting DNA and RNA synthesis.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Ewing's sarcoma
- Gestational trophoblastic neoplasia
- Osteosarcoma
- Rhabdomyosarcoma
- Endometrial cancer
Patient drug information
- Dactinomycin (Cosmegen) patient drug information (Chemocare)[3]
- Dactinomycin (Cosmegen) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/10/1964: Initial FDA approval
Also known as
- Generic names: AC-DE, Actinomycin D
- Brand names: Cosmegen, Dacmozen, Lyovac